Takeda–Rentschler: biologics contract manufacturing, 201901– supply service continued production for Shire in acquired manufacturing site in Milford

	Period	2019-01-03
	Partner, 1st	Shire plc (LSE: SHP, Nasdaq: SHPGY, TSX: SHQ)
	Today	Shire Ltd. (LSE: SHP, NASDAQ: SHPGY)
	Group	Takeda (Group)
	Partner, 2nd	Rentschler Biopharma Inc.
	Group	Rentschler (Group)
	Product	contract manufacturing (biologicals)
	Product 2	contract manufacturing (drugs)
	Index term	Shire–Rentschler: investment, 201812–201901 acquisition €na of Shire’s manufacturing facility in Milford, MA by Rentschler Biopharma SE

Rentschler Biopharma SE. (1/3/19). "Press Release: Rentschler Biopharma Completes Acquisition of U.S. Manufacturing Site". Laupheim & Milford, MA.

- Company’s first foothold in the U.S.

- Grants access to new technologies, innovation and talent

- Provides expanded capacity and flexibility

Rentschler Biopharma SE, a leading contract development and manufacturing organization (CDMO) for biopharmaceuticals, announced today that the Company has completed the acquisition of a manufacturing facility from an affiliate of Shire plc. The 93,000 square foot site is located near Boston in Milford, MA, USA. Under the terms of the agreement, Rentschler Biopharma will continue to manufacture for Shire at the site.

In addition, Rentschler Biopharma plans to further grow the development and manufacturing site to be leveraged as a CDMO for the development and manufacturing of complex biopharmaceuticals. About 70 employees currently work at the Milford site, all of whom have been offered continued employment at the site. The site will be Rentschler Biopharma’s first facility outside of Germany and a key part of the Company’s plans for future global growth. The purchase provides both expanded capacity and more flexibility to service its clients’ needs.

Dr. Frank Mathias, CEO of Rentschler Biopharma, said: “The acquisition of this modern facility fits perfectly with our strategy to further strengthen and secure our world-class CDMO position in a growing and changing market. The U.S. is a key market for Rentschler Biopharma, and this site gives us a firm foothold in this important area of growth, enabling us to better meet our clients’ needs.”

Dr. Ralf Otto, COO of Rentschler Biopharma, added: “We will continue to make investments in our business to ensure we have the advanced technologies to remain an innovation leader in the field and the capacity to remain competitive and grow with our clients. This includes future plans to qualify the Milford site as a multi-product manufacturing facility.”

Financial terms of the transaction were not disclosed.

About Rentschler Biopharma SE

Rentschler Biopharma SE, located in Laupheim, Germany, is a leading contract development and manufacturing organization (CDMO), focused exclusively on clients' projects. Rentschler Biopharma offers process development and manufacturing of biopharmaceuticals as well as related consulting activities, including project management and regulatory support. Rentschler Biopharma's high quality is proven by its long-standing experience and excellence as a solution partner for its clients. A high-level quality management system, a well-established operational excellence philosophy and advanced technologies ensure product quality and productivity at each development and manufacturing step. In order to offer optimal solutions across the entire value chain, the company has entered into a strategic alliance for formulation development with Leukocare AG and into a strategic partnership for fill & finish with Rentschler Fill Solutions GmbH. Rentschler Biopharma is a family-owned company employing more than 850 people.
For further information, please visit www.rentschler-biopharma.com.

Contact:

Rentschler Biopharma SE
Martina Sälzle
+49-7392-701-215
communications@rentschler-biopharma.com

MC Services AG
Eva Bauer
+49-89-210228-45
rentschler@mc-services.eu